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Background:  We assessed  maternal  23-valent  pneumococcal  polysaccharide  (23vPPV)  vaccine  efﬁcacy
(VE)  against  middle  ear  disease  and  pneumococcal  carriage  amongst  Australian  Indigenous  infants.
Methods:  In an  open  label,  allocation  concealed,  outcome-assessor  blinded,  community  stratiﬁed,  ran-
domised  controlled  trial,  healthy  pregnant  Indigenous  women  aged  17–39  years in  the  Northern  Territory
of  Australia  received  the  23vPPV  (1:1:1) at: 30–36  weeks  gestation,  birth,  or were  unvaccinated  (Clinical-
Trials.gov  NCT00714064).  Co-primary  outcomes  were  the  point  prevalences  of infant  middle  ear  disease
and  23vPPV-type  carriage  at age  7 months.
Results:  The  consent  rate  was  50%  (313/632).  Among  227  eligible  participants  randomised,  retention  rates
were  86%  (66/77)  controls;  89%  (67/75)  pregnancy  vaccinees;  88%  (66/75)  birth  vaccinees.  At  infant  age  7
months,  ear  disease  prevalence  was:  71%  (47/66)  controls,  63%  (42/67)  pregnancy  vaccinees,  76% (50/66)
birth  vaccinees;  and  23vPPV-type  carriage  was:  26%  (17/66)  controls,  18% (12/67)  pregnancy  vaccinees,
18%  (12/66)  birth  vaccinees.  For  pregnancy  vaccinees,  VE  was  12%  (95%  CI  −12%  to  31%)  against  infant  ear
disease  and  30%  (95%  CI −34% to 64%)  against  23vPPV-type  carriage.  In  a post-hoc  analysis,  VE  against
infant  ear  disease  concurrent  with  carriage  of  23vPPV  or related  types  was  51%  (95%  CI −2% to  76%). There
were  no serious  adverse  effects  following  receipt  of the 23vPPV  in  pregnancy  or at  birth.
Conclusions:  In  a high  risk  population,  our study  was  unable  to  demonstrate  efﬁcacy  of 23vPPV  in
pregnancy  against  the co-primary  outcomes  of either  all-cause  infant  ear  disease  or  23vPPV-type
nasopharyngeal  carriage  at age  7  months.  Efﬁcacy  against  ear  disease  concurrent  with  carriage  of  vaccine-
related  serotypes  (a  more  speciﬁc  outcome)  suggests  23vPPV  in  pregnancy  may  complement  childhood
pneumococcal  vaccination  programs.
© 2015  The  Authors.  Published  by  Elsevier  Ltd. This  is an  open  access  article  under  the CC  BY-NC-ND
license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Indigenous Australian children experience the highest pub-
lished rates of acute and chronic ear infections in the world [1].
∗ Corresponding author. Tel.: +61 8 89468508.
E-mail address: Michael.Binks@menzies.edu.au (M.J. Binks).
This may  result in permanent middle ear damage, hearing loss
and educational disadvantage. These infections are mainly bacterial
and the pneumococcus and non-typeable Haemophilus inﬂuenzae
are the predominant pathogens. Pneumococcal colonisation begins
within days of birth [2], months before direct immunological pro-
tection from infant pneumococcal conjugate vaccine (PCV) may  be
expected. Early recurrent pneumococcal infections cause inﬂam-
mation and mucosal damage that precede and predispose to the
http://dx.doi.org/10.1016/j.vaccine.2015.10.101
0264-410X/© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).
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Fig. 1. PneuMum participant ﬂow diagram.
development of chronic suppurative otitis media, chronic bronchi-
tis and bronchiectasis, all common among Indigenous populations
[1,3,4]. New strategies are needed to prevent, or delay, early pneu-
mococcal colonisation and middle ear disease.
Maternal immunisation with the 23-valent pneumococcal
polysaccharide vaccine (23vPPV) is one strategy that may  offer
infant protection from birth. Randomised controlled trials of
23vPPV in pregnancy have been conducted in Asia [5–8], Africa
[9,10] and the Americas [11,12]. These trials have consistently
demonstrated higher vaccine-speciﬁc antibody levels in maternal,
cord and infant blood, and in breast milk samples following 23vPPV
in pregnancy compared to controls [5–7,9–11]. Two  studies have
assessed infant pneumococcal carriage at age 6–7 months follow-
ing maternal 23vPPV. Whereas Munoz et al. [11] reported 34%
(13/38) carriage in the control group compared with 11% (2/18)
in the 23vPPV group, Lopes et al. [12] reported 15% (7/46) carriage
in the control group compared with 17% (7/42) among pregnancy
vaccinees and 18% (8/45) among birth vaccinees. Only one study,
O’Dempsey et al. [10] in the Gambia, investigated infant otitis
media. By one year of age, otitis media cases were reported in 4%
(3/75) of controls compared to none (0/75) among 23vPPV vacci-
nees. It remains unclear whether 23vPPV in pregnancy can impact
infant carriage and clinical outcomes. Recently, Daly et al. [13]
reported use of an investigational 9-valent PCV in pregnancy. The
vaccine was  well tolerated but appeared to interfere with subse-
quent infant serotype speciﬁc immune responses to the 7-valent
PCV (7vPCV) and increased the risk of otitis media before age 6
months, compared to controls.
Our randomised controlled trial, “PneuMum”, aimed to deter-
mine whether maternal 23vPPV, in pregnancy or at birth, could
reduce ear disease and 23vPPV-type nasopharyngeal colonisation
among infants at 7 months of age in a setting where both are
endemic.
2. Methods
2.1. Study design
We  conducted an open-label, allocation concealed, outcome-
assessor blinded, community stratiﬁed, three arm parallel group
(1:1:1) randomised controlled trial (Fig. 1) of maternal 23vPPV
(PNEUMOVAX® 23, Merck, USA).
2.2. Outcomes
Primary study outcomes at infant age 7 months were: preva-
lence of middle ear disease; and nasopharyngeal carriage of
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23vPPV-type pneumococci. Secondary outcomes included the
same assessments at infant age 1 and 2 months.
2.3. Participants, eligibility and randomisation
Pregnant Indigenous women in Darwin, Alice Springs and
remote communities of the Northern Territory of Australia were
recruited during public hospital antenatal screening visits (Royal
Darwin or Alice Springs Hospitals) between August 2006 and
January 2011. Eligibility, conﬁrmed prior to randomisation but no
earlier than 28 weeks gestation, was as follows: Indigenous Aus-
tralian women aged 17–39 years with a singleton uncomplicated
pregnancy (no existing or pre-existing condition judged by the
clinical investigator to make pregnancy high-risk); resident of the
catchment area; intending to give birth at a participating hospital;
no HIV, history of severe allergy, uncontrolled asthma or splenec-
tomy; and no history of 23vPPV within the previous three years.
At 30–36 weeks gestation (inclusive), eligible participants were
stratiﬁed by community of residence and randomised in blocks
of six by an independent statistician using a computerised ran-
dom number generator. Allocation concealment was  maintained
using sealed, opaque envelopes. Randomisation was  to one of three
groups:
• Pregnancy vaccinees—maternal 23vPPV at the randomisation
visit.
• Birth vaccinees—maternal 23vPPV within 72 h of infant birth.
• Control group—maternal 23vPPV offered at study exit (7 months
post-partum).
Throughout the study, infants received their routine PCV’s via
primary health care providers, recommended at 2, 4 and 6 months
of age [14,15]. Two PCV’s in use over this period for infants were the
7vPCV from June 2001 and the 10-valent pneumococcal H. inﬂuen-
zae protein D conjugate vaccine (10vPHiD-CV) from October 2009.
2.4. Sample collection and testing
Maternal nasopharyngeal swabs were collected at birth and
infant nasopharyngeal swabs at 1, 2 and 7 months. Pneumococcus
was isolated according to World Health Organization (WHO) guide-
lines [16], identiﬁed by -haemolysis, colony morphology and
susceptibility to optochin. Where identiﬁed, four colonies per swab
(including those of different morphologies) were serotyped by
Quellung reaction using serotype-speciﬁc antisera (Statens Serum
Institute, Copenhagen, Denmark). Non-typeable pneumococci and
optochin non-susceptible isolates were not considered further.
Nontypeable H. inﬂuenzae and Moraxella catarrhalis were cultured
using standard microbiological methods [17].
Pregnancy vaccinees had maternal blood collected immediately
prior to vaccination. All groups had maternal venous and cord
blood collected at birth and infant blood at age 7 months. Breast
milk was collected at birth, 1, 2 and 7 months post-partum. Serum
immunoglobin (Ig) G speciﬁc for each 23vPPV-type were measured
by trained laboratory staff blinded to the randomised allocation
using the methodology of a validated 3rd generation WHO  ELISA
[18,19]. Breast milk IgA speciﬁc for 15 of the 23vPPV-types were
measured using a novel ELISA method (Supplementary Method 1).
A comprehensive analysis of vaccine immunogenicity will be the
subject of a separate report.
2.5. Ear assessments
At the 1, 2 and 7 month visits, each child had bilateral clinical
ear assessments performed by trained research nurses using tym-
panometry and otoscopy. Tympanocentesis was  not performed.
An independent assessor (CW), blinded to the randomisation allo-
cation and the research nurse diagnosis, reviewed recordings of
the tympanometry and pneumatic video-otoscopy. Where the
independent assessor and research nurse diagnosis (ear disease
present/absent) was  concordant this was  accepted as ﬁnal. Where
discordant, a second independent assessor (PSM) reviewed the
tympanometry and pneumatic video-otoscopy blinded to all pre-
vious diagnoses and the randomisation allocation. The diagnosis
from the second independent review was  accepted as ﬁnal. The
presence or absence of ear disease was  based on the infant’s
worst ear and determined according to recommended guide-
lines for clinical practice in this population (Supplementary Table
1) [20]. Outcomes for sub-categories of ear disease are not
presented.
2.6. Analyses
Given an expected prevalence at age 7 months of 90% for middle
ear disease and 55% for nasopharyngeal carriage of 23vPPV-types
[1,21], the intended sample size of 210 participants (randomised
1:1:1), provided 80% power to demonstrate a 23% (90 to 69%) rela-
tive reduction in ear disease and a 45% (55 to 30%) relative reduction
in 23vPPV-type carriage.
Mother-infant pairs were considered to have successfully com-
pleted the study follow-up if the infant had both a nasopharyngeal
swab cultured and a valid independent ear assessment performed
(tympanometry and/or video-otoscopy) at the 7 month visit. Data
were analysed according to randomisation groups. Withdrawals,
infants lost to follow up, or those without assessment data for both
primary outcomes at age 7 months were excluded from analysis of
study outcomes.
Primary analyses were independent comparisons between the
point prevalence at age 7 months of ear disease and of 23vPPV-
type carriage between infants of the control group compared with
those of pregnancy vaccinees and birth vaccinees respectively. VE
was calculated (1 minus the risk ratio) with 95% conﬁdence inter-
vals (95% CI). Conﬁdence intervals were not adjusted for multiple
comparisons, those excluding zero were considered statistically
signiﬁcant. Secondary analyses were comparisons of any pneumo-
coccal carriage between controls and the respective vaccinees at
age 7 months as well as comparisons of ear disease and carriage
outcomes at ages 1 and 2 months.
A post hoc analysis at age 7 months, intended to maximise
sensitivity for ascertainment of potentially vaccine-preventable
ear disease, compared the prevalence of ear disease concurrent
with nasopharyngeal carriage of a 23vPPV-type or the related
serotype 6A (23v6A ear disease) between controls and the respec-
tive vaccinees. Serotype 6A was included based on demonstrated
cross-reactivity with serotype 6B (a 23vPPV-type) [22,23].
2.7. Ethics, clinical trial registration and protocol
Approval was obtained from the Human Research Ethics
Committee of the Northern Territory Department of Health
and Community Services and Menzies School of Health Research
(05/52). The trial was registered at clinicaltrials.gov (NCT00714064,
formerly NCT00310349) and the protocol is available online
at http://www.menzies.edu.au/icms docs/213758 PneuMum
Protocol.pdf. The 23vPPV was administered according to Aus-
tralian guidelines [14,15]. 23vPPV batch numbers were as follows:
2006—G1629, G1812; 2007—G1629, G3836, G3837, H5496;
2008—H5946, J3354; 2009—J3354, K1284, K2436, K2437, K3610,
L0220, N1234 N1419; 2010—L0224, N0397, N1127, N1419, N1516,
N1560, N1561, N3244, N3494, N3644; 2011—N3032, N3644,
N3851.
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Table 1
Participant characteristics.
Maternal characteristics at enrolment Control group n = 77 Pregnancy vaccinees n = 75 Birth vaccinees n = 75
Median maternal age (range), years 24 (17–38) 23 (17–39) 25 (17–37)
Household occupancy (range), people 5 (2–11) 4 (1–12) 4 (2–15)
n  (%) n (%) n (%)
Remote community residence 24 (31%) 23 (31%) 24 (32%)
Primigravida 29 (38%) 29 (39%) 22 (29%)
Smoker 34 (44%) 36 (48%) 36 (48%)
Inﬂuenza vaccine in pregnancy 16 (21%) 9 (12%) 14 (19%)
Infant characteristics at birth n = 76 n = 75 n = 74
Median gestational age (range), weeks 39 (35–42) 39 (35–41) 39 (34–41)
Median birthweight (range), grams 3381 (2132–4620) 3293 (2060–4425) 3334 (2080–4330)
n  (%) n (%) n (%)
Male  42 (55%) 36 (48%) 42 (57%)
Low  birth weight (<2500 grams) 4 (5%) 7 (9%) 4 (5%)
Premature (<37 weeks) 2 (3%) 7 (9%) 4 (5%)
Special or intensive care admission 16 (21%) 14 (19%) 15 (20%)
Infant characteristics at 7 month visit n = 66 n = 67 n = 66
Median visit age (range), months 7.2 (6.7–8.1) 7.2 (6.6–9.2) 7.2 (6.6–8.3)
n  (%) n (%) n (%)
Breast  fed 38 (58%) 43 (64%) 45 (68%)
Breast fed exclusive 28 (42%) 30 (45%) 35 (53%)
Mother smoking 37 (56%) 49 (69%) 37 (56%)
≥2  doses of any PCV 57 (86%) 56 (84%) 59 (89%)
Maternal characteristics are described at time of enrolment (prior to withdrawals/loss to follow-up). Infant characteristics at birth exclude 2 pre-birth withdrawals. Infant
characteristics at 7 month visit exclude 13 withdrawals and 15 lost to follow-up. PCV coverage calculated at 14 days prior to 7 month visit, included ≥2 doses of the 7-valent
pneumococcal conjugate vaccine (7vPCV; 59% overall) or the 10-valent pneumococcal Haemophilus inﬂuenzae protein D-conjugate vaccine (10vPHID-CV; 28% overall) which
were  in similar proportion in each group (data not shown). No infant received only two doses of a mixed schedule.
3. Results
3.1. Participants
The consent rate was 50% (313/632). Among 227 eligible partici-
pants subsequently randomised (Fig. 1), the retention rate was: 86%
(66/77) controls; 89% (67/75) pregnancy vaccinees; 88% (66/75)
birth vaccinees. Neither the withdrawals (n = 13) nor those lost to
follow-up at 7 months (n = 15) were differentially clustered by ran-
domisation group. Reasons for withdrawal were: moved outside
study catchment area (n = 3); personal (n = 6); not speciﬁed (n = 4).
Reasons for loss to follow-up were: moved outside study catch-
ment area (n = 6); unable to be located (n = 8); refusal of 7 month ear
exam (n = 1). Median time between receipt of the 23vPPV in preg-
nancy and birth was 6 weeks (IQR 4–8 weeks), range 1–10 weeks.
All participants that completed the 7 month follow-up received the
23vPPV as allocated.
Participant characteristics were similar among the allocated
groups (Table 1). Stratiﬁcation by location of residence resulted
in equal proportions of remote dwelling participants in each ran-
domisation group. Median maternal age at enrolment was 23–25
years with self-reported smoking rates high, both during preg-
nancy (44–48%) and at infant age 7 months (56–69%). Few women
(12–21%) received seasonal inﬂuenza vaccine during pregnancy,
whilst most infants (84–89%) had received ≥2 PCV (7vPCV or
10vPHiD-CV) doses at least 14 days prior to the 7 month visit.
3.2. Safety
Four pregnancy vaccinees (5%) reported local pain, swelling or
mild nausea post 23vPPV. Two  pregnancy vaccinees had preterm
births (35 weeks, 37 weeks) of otherwise healthy babies. Prevalence
of preterm birth, low birth weight, or neonatal intensive and spe-
cial care admission were similar for pregnancy vaccinees compared
with those not in the pregnancy vaccine group (Table 1). Two study
participants (non-pregnancy vaccinees) withdrew prior to birth.
3.3. Co-primary outcomes
At age 7 months (Table 2), middle ear disease prevalence among
infants was  71% (47/66) for the control group compared with 63%
(42/67) for infants of pregnancy vaccinees (VE 12%, 95% CI −12% to
31%) and 76% (50/66) for infants of birth vaccinees (VE −6%, 95% CI
−31% to 13%). At the same age, 26% (17/66) of infants in the con-
trol group had nasopharyngeal carriage of a 23vPPV-type compared
with 18% (12/67) for infants of pregnancy vaccinees (VE 30%, 95%
CI −34% to 64%) and 18% (12/66) for infants of birth vaccinees (VE
29%, 95% CI −36% to 63%).
Table 2
Co-primary ear disease and carriage outcomes at infant age 7 months.
Outcomes at infant age 7 months Control group n = 66 Pregnancy vaccinees n = 67 Birth vaccinees n = 66
n (%) n (%) VE1% (95% CI) n (%) VE2% (95% CI)
Ear disease 47 (71) 42 (63) 12 (−12,31) 50 (76) −6 (−31,13)
NP  carriage of a 23vPPV-type 17 (26) 12 (18) 30 (−34,64) 12 (18) 29 (−36,63)
NP: nasopharyngeal; VE1: vaccine efﬁcacy of pregnancy vaccinees versus control group; VE2: vaccine efﬁcacy of birth vaccinees versus control group; VE = 1 minus the risk
ratio.
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Table 3
Ear disease and nasopharyngeal pneumococcal carriage outcomes at 1, 2 and 7 month visits among infants of controls, pregnancy and birth vaccinees.
Infant age 1 month Infant age 2 months Infant age 7 months
Control group
n = 66
Pregnancy
vaccinees
n = 67
Birth vaccinees
n = 66
Control group
n = 66
Pregnancy
vaccinees
n = 67
Birth vaccinees
n  = 66
Control group
n = 66
Pregnancy
vaccinees
n = 67
Birth vaccinees
n  = 66
Blinded assessor diagnosed
infant ear disease, n (%)
13 (25%) 14 (25%)
p1 = 1.000
12 (28%)
p2 = 0.817
17 (33%) 21 (41%)
p1 = 0.418
23 (45%)
p2 = 0.228
47 (71%) 42 (63%)
p1 = 0.358
50 (76%)
p2 = 0.694
23vPPV carriage types, (n)
Serotype 3 1 0 0 0 1 0 1 (m1) 2 0
Serotype 6B (PCV) 0 0 0 1 2 0 0 2 1
Serotype 8 0 1 0 0 0 0 0 1 0
Serotype 9N 0 0 1 0 0 1 0 1 1
Serotype 9V (PCV) 0 0 0 1 0 0 0 0 0
Serotype 10A 0 1 0 1 1 2 1 2 (m5) 6 (m6)
Serotype 11A 1 0 2 1 0 1 1 1 0
Serotype 15B 0 0 0 0 1 0 4 (m1) (m3) 0 0
Serotype 19A 0 0 0 0 1 1 6 (m2) (m4) 2 3 (m7)
Serotype 19F (PCV) 0 1 1 1 2 0 1 (m2) 0 1
Serotype 22F 0 0 0 1 0 0 1 1 0
Serotype 23F (PCV) 0 1 0 0 0 1 0 0 0
Serotype 33F 0 0 0 0 0 0 4 0 0
Overall  23vPPV carriage, n (%) 2 (3%) 4 (7%)
p1 = 0.680
4 (8%)
p2 = 0.423
6 (10%) 8 (14%)
p1 = 0.777
6 (10%)
P2 = 1.000
17 (26%) 12 (18%)
p1 = 0.300
12 (18%)
p2 = 0.401
Non-23vPPV carriage types, (n)
Serotype 6A 0 0 0 0 0 1 4 0 1
Other  serotypes 6 5 5 12 11 11 22 (m3) (m4) 21(m5) 28 (m6) (m7)
Any pneumococcal carriage, n
(%)
8 (14%) 9 (15%)
p1 = 1.000
9 (17%)
p2 = 0.793
18 (31%) 19 (32%)
p1 = 1.000
18 (31%)
P2 = 1.000
41(62%) 32 (48%)
p1 = 0.118
39 (59%)
p2 = 0.859
No  nasopharyngeal swab, (n) 8 7 13 7 8 7 0 0 0
No  blinded tympanometry,
(n)
14 12 23 14 16 15 6 6 4
The primary infant ear disease outcome at age 7 months was determined by expert independent blinded assessors using tympanometry and video-otoscopy recorded by research nurses in the ﬁeld. Infants were only included
in  the table if they completed the 7 month study follow-up: both a nasopharyngeal swab cultured and a valid independent ear assessment performed (tympanometry and/or video-otoscopy). Difﬁculty obtaining high quality
video-otoscopy images at one or two month visits precluded their use for blinded diagnosis at these visits. Ear disease outcomes at age 1 and 2 months were determined solely by blinded assessment of the tympanometry.
Multiple  serotype carriage: (m1) 3 and 15B; (m2) 19F and 19A; (m3) 15C and 15B; (m4) 19A and 35F; (m5) 10A and 22A; (m6) 6 C and 10A; (m7) 6 C and 19A. PCV serotypes(PCV): pneumococcal serotypes contained in the 7vPCV or
10vPHID-CV. 23vPPV carriage: nasopharyngeal carriage of pneumococcal serotypes contained in the 23vPPV. p1: 23vPPV in pregnancy versus controls and p2: 23vPPV at birth versus controls; signiﬁcance determined using
Fisher’s  exact test. Missing data are described at the bottom of the table. Nasopharyngeal swabs were not available for 28 infants at 1 month and 22 infants at 2 months. No blinded assessment of the tympanometry was available
for  49 infants at 1 month, 45 infants at 2 months and 16 infants at 7 months.
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Fig. 2. Pneumococcal nasopharyngeal carriage isolates detected at infant age 7 months by serotype for controls, pregnancy and birth vaccinees. Individual (bars; left axis) and
cumulative (lines; right axis) serotypes detected in the nasopharynx of infants at 7 months of age are shown for each randomisation group. Multiple carriage of 23vPPV-types
occurred in two infants (infant 1: serotypes 15B and 3; infant 2: serotypes 19A and 19F), both of whom were in the control group. 23v types: pneumococcal serotypes
contained in the 23vPPV.
3.4. Secondary outcomes
At age 7 months, carriage of any pneumococcal serotype was
62% (41/66) for control infants compared with 48% (32/67) for
infants of pregnancy vaccinees (p = 0.118) and 59% (39/66) for
infants of birth vaccinees (p = 0.859) (Table 3). The most common
serotypes at age 7 months (Fig. 2), were non-23vPPV-types 6 C
and 16F (n = 23 and n = 18 infants respectively). Of the 23vPPV-
types (n = 41 infants in total), 19A, 10A, 15B and 33F predominated
(n = 28 infants in total). Serotypes 19A, 15B and 33F were each less
common among infants of vaccinees compared to controls while
serotype 10A was most common among birth vaccinees (Fig. 2,
Table 3). Five infants had serotype 6A carriage, four of which were
among the control group. Collectively, 7vPCV-types were infre-
quent at age 1 (n = 3), 2 (n = 8) and 7 months (n = 5).
Maternal 23vPPV-type carriage rates at birth were 2% (3/132)
among non-pregnancy vaccinees compared to 6% (4/67) among
pregnancy vaccinees (p = 0.228). Difﬁculty obtaining high qual-
ity video-otoscopy images at one or two month visits meant the
blinded assessor diagnosis at these visits relied solely on the tym-
panometry recording. At the one and two month visits, neither the
prevalence of infant middle ear disease nor nasopharyngeal car-
riage of 23vPPV-types was signiﬁcantly different between controls
and respective maternal vaccination groups (Table 3).
Immune responses in maternal sera, cord blood and breast
milk were consistently higher amongst pregnancy vaccinees than
controls for the commonly isolated serotypes 19A, 15B, 33F and
10A, though the responses varied by serotype (Fig. 3). In terms of
magnitude, antibody concentrations for serotypes 19A, 15B and
33F were higher than serotype 10A. For all other 23vPPV-types
(data not shown): maternal serum IgG concentrations were signif-
icantly higher post-23vPPV compared to controls, either at birth or
1 month post-partum (including for the 23vPPV-related serotype
6A); IgG concentrations in cord blood were signiﬁcantly higher
amongst pregnancy vaccinees than controls (but not for serotype
6A); and infant serum IgG concentrations at age 7 months were
similar across all three groups, including to the PCV serotypes with
no signiﬁcant evidence of interference from maternal vaccination.
In breast milk, when compared to controls, pregnancy vaccinees
had higher IgA for 14/15 serotypes tested at 1 month, 15/15 at 2
months and 13/15 serotypes at 7 months while birth vaccinees had
higher IgA for 12/15 serotypes at 1 month, 13/15 serotypes at 2
months and 6/15 serotypes at 7 months. Overall serotype-speciﬁc
breast milk IgA was generally higher among pregnancy compared
to birth vaccinees at 1 month (0.9 to 1.61 fold), 2 month (1.2 to
1.5 fold) and 7 months (1.1 to 1.7 fold). IgA concentrations were all
<0.4 g/ml.
3.5. Post hoc analysis
At age 7 months, infant ear disease prevalence associated with
concurrent carriage of a 23v6A serotype (Supplementary Table 2,
Fig. 4) was 27% (18/66) in the control group compared with 13%
(9/67) among pregnancy vaccinees (VE 51%, 95% CI −2% to 76%)
and 17% (11/66) among birth vaccinees (VE 39%, 95% CI −19% to
69%). In contrast, the prevalence at age 7 months of ear disease
associated with non-23v6A serotypes, nontypeable H. inﬂuenzae
and/or M.  catarrhalis in the absence of pneumococcus, or where no
detectable pathogen was found, were similar between vaccinees
and controls (Fig. 4).
At age 7 months, 12 serotypes were associated with the 23v6A
ear disease in 38 children (Supplementary Table 2). Of these,
serotypes 19A, 10A, 15B, 33F and 6A predominated (76%; 29/38).
Serotypes 19A, 15B, 33F and 6A were proportionally more common
among controls than the vaccinees whereas serotype 10A was more
common among the vaccinees than the controls. The other seven
children with 23v6A ear disease had serotypes 3, 6B, 8, 9N, 11A,
19F, 22F (each serotype had ≤1 occurrence per group). There were
no children with ear disease and concurrent nasopharyngeal car-
riage of the other 23vPPV-types (1, 2, 4, 5, 7F, 9V, 12F, 14, 17F, 18C,
20 & 23F). Only three infants (one in each group) had ear disease
associated with a PCV-type (7vPCV or 10vPHiD-CV).
4. Discussion
In our outcome-assessor blinded trial, we  were unable to
demonstrate signiﬁcant efﬁcacy of 23vPPV in pregnancy against
either infant ear disease (VE 12%, 95% CI −12% to 31%) or
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Fig. 3. Immunogenicity of 23vPPV in venous blood, cord blood and breast milk among controls, pregnancy and birth vaccinees for serotypes 19A, 15B, 33F and 10A. Geometric
mean  concentrations (GMC) of antibodies (immunoglobin, Ig) to four commonly carried serotypes (19A, 15B, 33F and 10A) as measured in mothers (venous blood, cord blood
and  breast milk) and their infants (blood) at scheduled study visits for each randomisation group. For the other 23vPPV-types, relative trends in antibody concentrations
were  similar by visit and vaccine group, despite variations in absolute magnitude.
Fig. 4. Nasopharyngeal carriage concurrent with ear disease at infant age 7 months among controls, pregnancy and birth vaccinees.
The  proportion of infants with Any ear disease (bold lines) are sub-grouped (dotted lines) as follows: Any pneumococcus: concurrent nasopharyngeal carriage of any
pneumococcal serotype; 23v6A ear disease: ear disease with concurrent nasopharyngeal carriage of a 23v6A serotype (black wedge, exploded). Note: Two infants, both in
the  control group, had ear disease with concurrent multiple 23v6A serotypes (serotypes 15B and 3; 19A and 19F). Infants with multiple serotype carriage of a 23v6A and a
non23v6A serotype are shown exclusively within the 23v6A wedge: one infant of pregnancy vaccinees (serotypes 10A and 22A), two infants of birth vaccinees (serotypes
6C  and 10A; 6C and 19A) and two control infants (serotypes 15B and 15C; 19A and 35F). NTHi: Nontypeable Haemophilus inﬂuenzae. Mcat: Moraxella catarrhalis. Pnc:
Pneumococcus.
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23vPPV-type nasopharyngeal carriage (VE 30%, 95% CI −34% to
64%) at age 7 months nor for the same outcomes following 23vPPV
at birth (Table 2). We  achieved our intended sample size but
had reduced study power due to lower than predicted prevalence
amongst the controls of the a priori outcomes of ear disease (actual
71%; predicted 90%) and nasopharyngeal carriage of 23vPPV-types
(actual 26%; predicted 55%) at infant age 7 months.
In post hoc analysis, the risk of ear disease concurrent with
nasopharyngeal carriage of a 23vPPV-type or the vaccine-related
serotype 6A (23v6A ear disease) was reduced by 51% (95% CI −2%
to 76%) among infants of pregnancy vaccinees compared with con-
trols. The lack of vaccine impact against other (non-23v6A) ear
disease suggests the reduction was vaccine-speciﬁc. High mater-
nal post-vaccination antibody concentrations to serotypes 19A,
15B and 33F but not to serotype 10A are also consistent with
the observed impact against ear disease associated with these
serotypes. We  advocate the use of this more speciﬁc outcome
strategy in future pneumococcal vaccine trials, particularly where
tympanocentesis is not possible.
Previous maternal 23vPPV trials have also failed to demonstrate
an impact against infant acute respiratory infections [12], otitis
media [10] or pneumococcal carriage [11,12]. In contrast to the
PneuMum study, these trials were smaller and conducted in lower
risk settings without a routine childhood PCV program in place.
Most infants (84–89%) in our study had received ≥2 doses of a
PCV (7vPCV or 10vPHiD-CV) at least 2 weeks prior to the seven
month visit and few (n = 5) had carriage of a PCV serotype. Any
effect against ear disease or pneumococcal carriage in our setting
was largely conﬁned to 23vPPV serotypes not contained in PCV’s.
Undertaking a maternal vaccination trial in this high risk setting
was challenging; however, the consent rate (50%) and achievement
of the intended sample size, demonstrate that such studies are pos-
sible. Engagement with participants, local communities [24], an
Indigenous Reference Group [25] and the Independent Data Safety
Monitoring Board that included community representation were
integral to the success of this trial.
In rural and remote regions of Australia’s Northern Territory the
risk of ear disease remains high. In our control group at 7 months
of age, seven out of ten children had middle ear disease. For every
three control children with ear disease at age 7 months, one was
potentially preventable by 23vPPV in pregnancy, one was  associ-
ated with a non-vaccine type whilst the other had no associated
pneumococcal carriage. Our data suggests the 23vPPV in pregnancy
halved the preventable fraction of infant ear disease at 7 months but
lacked the ability to impact all-cause ear disease, perhaps similar to
the lack of effect against all-cause pneumonia in adults [26]. Future
use of maternal 23vPPV in this region is likely to be conﬁned to
preventing the small fraction of infant ear disease associated with
common non-PCV serotypes (examples 15B and 33F).
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